|
|
|
|
Vol. 57, Issue 2, 359-366, February 2000
Departments of Biological Sciences (D.S., W.J., A.F., M.K., F.G.B., H.T.S.) and Chemistry and Biochemistry (C.F., J.P., L.L.), University of South Carolina and the South Carolina Cancer Center (H.T.S.), Columbia, South Carolina; and Department of Molecular Pharmacology and Biophysics (W.M.), University of Virginia, Charlottesville, Virginia.
| |
Abstract |
|---|
|
|
|---|
Drug-resistant variants of thymidylate synthase (TS) can potentially be
used in gene therapy applications to decrease the myelosuppressive side
effects of TS-directed anticancer agents or to select genetically
modified cells in vivo. Mutations of proline 303 of human TS confer
resistance to TS-directed fluoropyrimidines and antifolates (Kitchens
et al., 1999
). We generated the corresponding variants in
Escherichia coli TS (ecTS), position 254, to better understand the mechanism by which mutations at this residue confer resistance. In addition, because ecTS is intrinsically resistant to
several antifolates when compared with human TS, we suspected that
greater resistance could be achieved with the bacterial enzyme. The
P254L enzyme conferred >100-fold resistance to both raltitrexed and
5-fluoro-2'-deoxyuridine (FdUrd) compared with wild-type ecTS. Four additional mutants (P254F, P254S, P254G, and P254D), each of which complemented growth of a TS-deficient cell line, were generated, isolated, and characterized. Steady-state values of Km for dUMP and
kcat were not substantially different among
the variants and were comparable with the wild-type values, but
Km for methylenetetrahydrofolate
(CH2H4PteGlu) was >10-fold higher for
P254D. Values of kon and
koff for nucleotide binding, which were
obtained by stopped-flow spectroscopy, were virtually unchanged among
the mutants. Drastic differences were observed for
CH2H4PteGlu binding, with
Kd values >15-fold higher than observed
with the wild-type enzyme; surprisingly, the proposed isomerization
reaction that is very evident for the wild-type enzyme is not observed with P254S. The decrease in affinity for
CH2H4PteGlu correlates well with
Ki values obtained for three TS-directed
inhibitors. These results show that mutations at Pro-254 specifically
affect the initial binding interactions between enzyme and cofactor and also alter the ability of the mutant enzymes to undergo conformational changes that occur on ternary complex formation. The crystal structure of P254S was determined at 1.5 Å resolution and is the most precise structure of TS available. When compared with wild-type TS, the structure shows local conformational changes affecting mostly Asp-253;
its carbonyl is rotated approximately 40°, and the side chain forms
an ion pair with Arg-225.
| |
Introduction |
|---|
|
|
|---|
Effective
drug treatment of human malignancies can be hampered by
myelosuppressive side effects that result in increased susceptibility to life-threatening infections. The understanding of the molecular events leading to drug resistance has allowed investigators to test the
feasibility of transferring genes that confer such resistance into
normal cells. Gene transfer of chemoprotecting genes into bone marrow
cells has the potential of protecting multiple hematopoietic lineages
from the deleterious effects of chemotherapy, thereby allowing more
aggressive chemotherapeutic dosing (reviewed in Koc et al., 1996
). In
addition to attenuating myelosuppression, genes that confer
chemoprotection can provide a selective advantage to genetically
modified hematopoietic cells. Studies using gene transfer of the cDNA
that encodes MDR-1 or dihydrofolate reductase (DHFR) provide
evidence that selectable markers can be used for in vivo enrichment of
gene-modified cells (Sorrentino et al., 1992
; Spencer et al., 1996
;
Allay et al., 1998
).
Although the use of MDR-1 and DHFR have advanced to clinical trials
(Hesdorffer et al., 1994
; O'Shaughnessy et al., 1994
; Deisseroth et
al., 1996
), there is a need to adapt such technologies to the
attenuation of side effects of other important neoplastic agents.
Thymidylate synthase (TS) is an excellent candidate for drug-resistant
gene therapy, because it is a pre-eminent target for the design of new
anticancer agents [e.g., raltitrexed (Tomudex) and BW1843U89].
In addition, it is the target of mainstream chemotherapy agents (e.g.,
5-FU); the recombinant enzyme has been well-characterized, and the cDNA
that encodes TS is relatively small (<1,000 base pairs) (Davisson et
al., 1989
; Carreras and Santi, 1995
; Reilly et al., 1995
; Touroutoglou
and Pazdur, 1996
; Spencer et al., 1997
).
TS catalyzes the transfer of a methyl group from
methylenetetrahydrofolate
(CH2H4PteGlu) to dUMP,
forming TMP. Inhibition of TS results in apoptotic cell death that is
caused by intracellular thymidine depletion. Acquired resistance to TS
inhibitors is a multifactorial process that can include amplification
and/or mutation of the TS gene. In cells adapted to high concentrations
of FdUrd, we showed that TS gene amplification in addition to mRNA and
enzyme overproduction were commonly observed (Kitchens et al., 1999
). For some adapted cell lines, overproduction of mRNA and protein were
discordant, indicating that post-transcriptional mechanisms are
involved in the resistance phenotype. A Pro to Leu substitution at
residue 303 of human TS was identified and shown to be the effector of
5-fluoro-2'-deoxyuridine (FdUrd) resistance.
Crystal structures and rate constants governing individual steps in the catalytic mechanism of human TS are not available. Therefore, to better understand the mechanism by which mutations at residue 303 of human TS confer drug resistance, we generated the corresponding mutation in Escherichia coli TS (ecTS), which is structurally and kinetically well-characterized. In addition, because ecTS is intrinsically resistant to several TS-directed antifolates, it was anticipated that greater resistance could be achieved using the bacterial enzyme. Five amino acid substitutions were generated at residue 254, which is homologous to residue 303 of human TS, and steady-state and transient-state kinetic parameters were determined for each. The crystal structure of P254S TS was determined and used to explain its kinetic and mechanistic variations from the wild-type enzyme. The results show that mutations at Pro-254 decrease enzyme stability and decrease the affinity of the enzyme for CH2H4PteGlu and for three TS-directed antifolates but that the substitutions have little effect on nucleotide binding or the rate-limiting step of catalysis. The drastic decrease in antifolate affinity suggests that variants at residue 254 in ecTS may be suitable for use as drug-resistant markers in gene therapy applications.
| |
Experimental Procedures |
|---|
|
|
|---|
Site-Directed Mutagenesis and Growth Complementation
Studies.
The gene encoding ecTS, a gift from Dr. Dallas (Glaxo
Wellcome, Research Triangle Park, NC), was amplified by
polymerase chain reaction (PCR) to introduce XbaI and
ClaI sites at the 5'- and 3'-ends of the coding region,
respectively. The amplified sequence was cloned into the
XbaI/ClaI sites of pBluescript SK
(Stratagene, La Jolla, CA), which generated pBSecTS, transformed
into XL-1 Blue bacterial cells, and sequenced to confirm the integrity
of the ecTS gene. Mutations at residue 254 were produced by PCR
mutagenesis using the overlap extension method to generate a 570-base
pair product (Ho et al., 1989
). The PCR product was digested with
NsiI and ClaI and cloned into the
NsiI/ClaI sites of pBSecTS. The entire cloned
region was sequenced to confirm the presence of the mutation and assure
the absence of undesired mutations.
2913. Transformed cells were grown in
defined medium with tetracycline (selects for
2913 cells) and
ampicillin (selects for transformed cells) but which lacked thymidine
(selects for active TS mutants).
Protein Purification.
Cell free extracts were
obtained from 2 g of wet cells by five 30-s consecutive sonication
cycles (Branson Sonifier 450; Danbury, CT) in 25 ml of degassed
QA buffer (50 mM Tris, 14 mM 2-mercaptoethanol, and 1 mM EDTA, pH 7.5),
centrifuged at 11,000g for 30 min, and applied to a DEAE
Affi-Gel Blue (Sigma, St. Louis, MO) column (2.5 × 15-cm)
pre-equilibrated in QA buffer. The column was washed with three column
volumes of QA buffer, two column volumes of 100 mM KCl, then by two
column volumes of 200 mM KCl in QA buffer. Enzyme activity routinely
eluted in 200 mM KCl. The eluted enzyme was dialyzed against QA buffer
and applied to a 2.5 × 20-cm Q-Sepharose FPLC column (Amersham
Pharmacia Biotech, Piscataway, NJ) that had been equilibrated
with degassed QA buffer. Elution was accomplished by using a 500-ml
linear gradient of 200 to 600 mM KCl in QA buffer. Fractions were
monitored for TS activity, which typically eluted between 360 and 420 mM KCl. Enzyme purity was assessed by SDS polyacrylamide gel
electrophoresis, and purified proteins were stored in 15% glycerol at
70°C.
Kinetic Characterization of ecTS and Pro-254
Variants
Steady-State Determinations.
The concentration of
purified enzymes was determined using a molar extinction coefficient at
280 nm of 1.13 × 105
M
1 cm
1, and the number
of binding sites was determined by FdUMP titration of protein
absorbance at 330 nm. The concentrations of 1/2 binding sites
were in good agreement with the concentrations determined by UV
absorbance at 280 nm. The value of Km(dUMP)
was determined using concentrations of dUMP between 1 and 100 µM with
100 µM CH2H4PteGlu,
except 500 µM CH2H4PteGlu
was used for P254D. The value of
Km(CH2H4PteGlu) was determined using
CH2H4PteGlu concentrations in the range of 6 to 300 µM in the presence of 100 µM dUMP.
Reactions were performed at 20°C in 100 mM Tris-HCl (pH 7.4), 1 mM
EDTA, and 14 mM 2-mercaptoethanol, and activity was followed by
measuring the absorbance at 340 nm. Velocity values were plotted versus the concentration of ligand, and the values of
Km and kcat
were determined using the program KaleidaGraph (Synergy Software,
Reading, PA). Values of Ki were
determined using the program EZ-fit (Perrella Scientific, Amherst,
NH) with enzyme concentrations ranging from 20 to 200 nM, dUMP
concentrations of 100 µM, and
CH2H4PteGlu concentrations 3 times the Km values.
Kinetic Characterization of ecTS and Pro-254
Variants
Transient-State Determination.
Ligand binding was
followed on an Applied Photophysics (Surrey, UK) SX-18 stopped-flow
fluorometer/spectrophotometer at 20°C in activation buffer
(100 mM Tris buffer, pH 7.4, containing 10 mM 2-mercaptoethanol) using
an excitation wavelength of 295 nm and emission wavelengths 330 nm as
previously reported (Spencer et al., 1997
). Enzymes and ligands were
diluted in activation buffer to concentrations 2 times that indicated
within the text or in figure legends. After collection, data were
computer-fitted by nonlinear least-squares analysis to equations
describing single or multiple exponential terms using KaleidaGraph
3.0.1. At least five traces were averaged for every ligand
concentration. The entire experiment for the determination of the
association and dissociation rate constants was repeated a minimum of
two times for each mutant.
Survival Curves.
The cDNAs that encode wild type and P254L
were cloned into the SacII/XhoI sites of the
HaMSV retroviral vector (Sorrentino et al., 1992
; Spencer et
al., 1996
) and transfected into the TS-deficient Chinese hamster lung
cell line RJK88.13. Selection of transfected cells was accomplished by
removing thymidine from the medium. Survival curves were
generated by plating 40,000 cells/25-cm2 flask
with various concentrations of TS inhibitors. After 5 to 7 days,
surviving cells were counted after trypan blue staining. At least three
flasks were used for each concentration of drug.
Determination of Protein Levels
FdUMP Binding Assay.
Extracts from Chinese hamster lung cells that contained ecTS constructs
were prepared by sonication from two nearly confluent 100-mm dishes.
Reaction mixtures contained, in 500 µl, 50 µg of cell free
extract, 300 µM
CH2H4PteGlu, 100 µl of
Morrison buffer (120 mM Tris, 60 mM MES, 60 mM acetic acid, pH 7.2) and
either 100 or 200 nM [3H]FdUMP. Following
1 h of incubation at room temperature, 125 µl of 50%
trichloroacetic acid was added and centrifuged at 13,000g for 5 min. The pellet was washed four times with 10% trichloroacetic acid and resuspended in 2 N NaOH, 50% ethanol and counted.
Concentrations of TS are expressed as picomoles of FdUMP bound per
milligram of protein.
Crystallization of P254S TS. The purified enzyme was dialyzed against a buffer containing 1 mM EDTA, 10 mM 2-mercaptoethanol, 100 mM ammonium sulfate, and 20 mM potassium phosphate at pH 7.5 for 72 h. Crystals were grown using the vapor diffusion method in the hanging drop setup. Typically, 5 µl of TS solution at 20 mg/ml was mixed with an equal volume of a precipitating well solution (58% saturated ammonium sulfate, 20 mM 2-mercaptoethanol, and 100 mM Tris-HCl, pH 8.8) and allowed to equilibrate with the well. Crystals appeared after 21 days and grew to the size of 0.4 mm within 1 week.
Crystallography.
A crystal measuring approximately .4 × .4 mm was transferred to a cryoprotectant solution and flash-frozen in
liquid nitrogen. The data were collected at the SBC line of
Advanced Photon Source at Argonne National Laboratory (Argonne,
IL) using X-rays of 0.9793 Å in wavelength. Two sets of data
were collected at high and low resolution with a 3 × 3 CCD
array detector, and were indexed, integrated, and scaled with the HKL
2000 suit of programs (Otwinowski and Minor, 1997
). The
strategy option was used for collecting all possible independent
reflections with minimum radiation damage to the crystal. In the first
pass, oscillation frames were collected to record the high resolution
data. The second pass was used to remeasure reflections that suffered
from intensity overflow during the first pass. The detailed collection
strategy is summarized in Table 5. The structure of S167T mutant
(unpublished data) with the appropriate amino acid sequence
modifications was used as the starting model in molecular replacement
using CCP4 software (Computational Collaborative Project, 1994
), and
the data were optimized with the CNS software (Brunger et al.,
1998
) using positional and temperature refinements. Electron density
maps calculated with 2Fo
Fc, and Fo
Fc coefficients were inspected to introduce corrections manually to the model with the interactive graphics program
CHAIN (Sack and Quiocho, 1997
).
| |
Results |
|---|
|
|
|---|
Location of Pro-254.
Pro-254 in ecTS is located at a bend 11 amino acids from the C-terminal isoleucine residue. Its side chain is
not exposed to solvent but makes contact with the side chain of Arg-48.
Figure 1 shows that the proline does not
make direct contact with either bound nucleotide or folate (Hyatt et
al., 1997
). However, the residue is situated in the middle of the final
bend that directs the C-terminal residues toward the active site. The
C-terminal residues, particularly the final four residues, are known to
be crucial for CH2H4PteGlu
binding.
|
Resistance Conferred by the P254L Mutant of ecTS.
Substitution
of leucine for proline at residue 303 of human TS confers resistance to
fluoropyrimidines and antifolates (Kitchens et al., 1999
). To determine
whether the homologous substitution in ecTS confers resistance, we
engineered the corresponding mutation at residue 254 of ecTS. The cDNAs
that encode wild-type ecTS or the P254L mutant were introduced into the
HaMSV retroviral vector and transfected into the TS-deficient cell line
RJK88.13. Both constructs complemented cell growth in media lacking
thymidine, and transfected cells had similar levels of TS protein
expression (1.2 pmol/mg of protein) as determined by radiolabeled FdUMP
titrations and similar growth rates. Similar to human TS, but to a much
greater extent, substitution of leucine for proline confers resistance to raltitrexed (>100-fold) and FdUrd (>500-fold) (Fig.
2), indicating that ecTS is more
sensitive to the Pro to Leu substitution than is the human enzyme.
Cells transfected with the wild-type or mutant constructs were equally
sensitive to the DHFR directed inhibitors methotrexate and
trimetrexate.
|
Purification of Pro-254 Variants.
To determine the effects of
amino acid substitutions at position 254, proline was substituted with
residues that represent various classes of amino acids, including
leucine, glycine, phenylalanine, serine, and aspartic acid. With the
exception of leucine, all enzymes complemented the growth of
TS-deficient
2913 bacterial cells and constituted about 15% soluble
protein. The P254L enzyme was not present in cell-free extracts but
precipitated presumably into inclusion bodies; only inactive protein
was recovered in the cell sonicates (data not shown). Wild-type and the
remaining four variants were isolated to >90% purity. In vitro
stability studies using 1 µM purified enzyme and 50 µM dUMP showed
that, with the exception of glycine, the variants were less stable at 37°C than wild-type ecTS (data not shown). Whereas the half-life of
wild-type ecTS was 90 min, the half-life of P254F, P254S, and P254D were approximately 50 min.
Steady-State Kinetic Constants. Values of Km for dUMP and CH2H4PteGlu, kcat and catalytic efficiencies (measured as kcat/Km) are shown in Table 1. The values for kcat and Km(dUMP) are similar among the enzymes, with P254D having the greatest variance from the wild-type value for both kcat and Km(dUMP), but only by factors of 1.5 and 2.8, respectively. P254G, P254F, and P254S enzymes have Km(CH2H4PteGlu) values similar to the wild-type enzyme, whereas that for the P254D enzyme is >10-fold higher. Although the catalytic efficiencies of P254G, P254F, and P254S are similar to the wild-type enzyme, the decrease in kcat and increase in Km(CH2H4PteGlu) for P254D lowers the catalytic efficiency of this enzyme by approximately 15-fold.
|
Transient State Kinetic Constants
dUMP Binary Complex
Formation.
Because the values of Km
depend on several rate constants, specific values that govern
individual steps along the catalytic pathway were determined. For ecTS
the binding of dUMP is a simple bimolecular association reaction
opposed by a unimolecular dissociation reaction. The binding of dUMP
causes quenching of intrinsic protein fluorescence, the rate of which
can be used to determine kon and koff values using the relationship
kobs = kon
[dUMP] + koff (Spencer et al., 1997
).
Table 2 shows
kon, koff, and
Kd (as defined by koff/kon)
values for the wild-type and P254F, P254S, and P254D enzymes. Because
these values are not substantially different among the enzymes, these
results show that nucleotide binding is not severely affected by the
Pro-254 mutations.
|
Transient State Kinetic
Constants
CH2H4PteGlu binding.
It has
been shown that binding of
CH2H4PteGlu into the
ternary complex of wild-type ecTS·dUMP can be described by Scheme
1, where L = CH2H4PteGlu and
E = ecTS·dUMP and P = product of
reaction (Spencer et al., 1997
).
|
|
|
Binary Complex Formation between FdUMP and Enzyme. Because a P303L mutation of human TS was identified in a FdUrd resistant cell line, rate constants governing FdUMP binary complex formation for the P254D enzyme were determined. Although the kon and koff values for dUMP binding were not substantially affected by the mutations, the dissociation constant (Kd) for FdUMP is >3-fold higher (Table 4). The difference is mainly due to an increase in the value of koff (Table 4). Compared with the binding of dUMP to P254D, FdUMP binds with >6-fold weaker affinity.
|
Transient State Kinetic Constants
AG337 binding.
Many
tight-binding antifolate-based inhibitors of TS have recently been
developed. We used stopped-flow spectroscopy to determine the effects
of Pro-254 substitutions on the binding of raltitrexed, BW1843U89, and
AG337. Raltitrexed and BW1843U89 have high values of
kon (>60 µM
1
s
1) and very low values of
koff (<5 s
1).
Because koff is so low, it is impractical
to compare the effects of Pro-254 mutations on the binding of these
ligands. However, the initial binding of AG337 to wild-type ecTS has a
koff value of approximately 70 s
1, allowing for an accurate comparison of the
effects of Pro-254 mutations on the binding of an inhibitor that
occupies the cofactor binding site.
1, indicating that
a conformational change occurs on AG337 binding. The binding of AG337
to the P254D enzyme is best described by a single exponential, and the
observed rate of binding is linearly dependent on the concentration of
AG337, which was used to calculate values of
kon and koff
(Table 4). The values of kon for AG337 binding to wild-type ecTS and to the P254D enzyme are similar, but the
value of koff is approximately 7-fold
higher for P254D, increasing the value of
Kd >7-fold (Table 4).
Affinity of TS-Targeted Inhibitors and the Ability to Confer Drug
Resistance.
Compared with human TS, wild-type ecTS has higher
Ki values for raltitrexed and AG337 but a
similar Ki value for BW1843U89, which is
consistent with previously reported results (Jackson et al., 1993
). The
P254S and P254F mutants and wild-type ecTS have similar
Ki values for these three inhibitors.
However, Ki values are drastically
increased for P254D, the greatest increase is observed with raltitrexed
(>10-fold compared with wild-type ecTS and >100-fold compared with
human TS) (Fig. 4A). P254D was cloned
into the HaMSV retroviral vector and transfected into the TS
cell line RJK88.13, and transformants were
selected by removing thymidine from the growth media. Compared with
cells transfected with either human TS or wild-type ecTS at similar
enzyme levels (1.5 ± 0.3 pmol bound FdUMP/mg of protein), P254D
conferred the greatest resistance to raltitrexed (Fig. 4B).
|
Crystallographic Data Measurement and Refinement.
Steady-state
kinetic and thermodynamic properties of P254S are virtually unchanged
when compared with the wild-type enzyme. However, this mutation appears
to affect ligand-induced isomerization. In an effort to better
understand the effects of this mutation, high resolution data were
collected from crystals of P254S to 100% completion with a mosaic
spread of 0.37° and an Rsymm of 12%. The
detailed collection strategy is summarized in Table
5. The completeness is also 100% in the
highest resolution shell, 1.55 to 1.50, with 4008 reflections having
I > 2
(I). The low resolution set was
96.7% complete to 2.10 Å with an Rsymm of
10%. The data were merged after rejecting intensity-saturated and weak reflections to give a 99.9% complete set of data to 1.50 Å. Merging of the two data sets yielded an Rmerge of
6.6 and 91.1% of the reflections having
I/
(I) > 2. After several rounds of
refinement and modeling, the 2Fo
Fc electron density map was superb; it revealed holes in aromatic and proline rings, and a bulge of density for every carbonyl group. However, electron density was missing for a
few side chains, especially residues 19-22 at the
-bend located
between helix A and strand I, which are partially disordered. The data
were refined to a final R-factor of 22% and has been deposited at the Protein Data Bank as entry 1qqq. Figure
5 shows that the effects of the P254S
mutation are local and that the most significant difference between the
wild-type enzyme and P254S is a 40o rotation of
the carbonyl plane of Asp-253. An ion pair is then capable of forming
between Asp-253 and Arg-225. Although the positioning of the final four
C-terminal residues (261-264) of P254S is slightly shifted compared
with the wild-type enzyme, residues 257-260 are virtually unchanged.
|
|
| |
Discussion |
|---|
|
|
|---|
Clinical trials that introduce chemoprotecting genes into
hematopoietic cells are aimed at protecting the recipient from the myelosuppressive side effects of chemotherapy (O'Shaughnessy et al.,
1994
; Hesdorffer et al., 1994
; Deisseroth et al., 1996
). Transfer of
genes encoding MDR-1 and DHFR have advanced to clinical trials and are
model systems for the study of retroviral transfer of genes that confer
drug resistance (Hock and Miller, 1986
; Flasshove et al., 1995
; May et
al., 1996
). Because dose-limiting toxicities associated with inhibitors
of TS are myelosuppression and mucositis, we have been investigating
gene transfer of drug-resistant variants of TS. Previously we showed
that human and ecTS can be transferred using recombinant retroviruses
and that retroviral gene transfer of the human TS Y33H variant
conferred resistance to FdUrd and AG337. However, the degree of
resistance was only 3- to 5-fold relative to nontransduced cells (Fantz
et al., 1998
). It is, therefore, necessary to identify additional
variants that confer greater drug resistance.
Recently, Bertino and colleagues identified drug-resistant variants of
human TS using ethyl methanesulfonate to generate random mutants. Two
variants were identified, D49G and G52S, that had catalytic
efficiencies similar to the wild-type enzyme and that conferred
resistance to AG337 and FdUrd but not to raltitrexed or BW1843U89 (Tong
et al., 1998a
). Resistance to raltitrexed and BW1843U89 was achieved
using site-directed mutagenesis to target residues (Ile-108 and
Phe-225) within the folate binding site, (Tong et al., 1998b
). Although
the catalytic efficiency
(kcat/Km for
CH2H4PteGlu) of the variant
I108A is >200-fold lower than the wild-type enzyme, this variant
conferred antifolate resistance to transfected mouse bone marrow cells.
Landis and Loeb used random sequence mutagenesis to target 13 active
site residues of human TS and identified a triple mutant,
A197V/L198I/C199F, that had a FdUMP dissociation constant 20-fold
higher than values obtained for wild-type human TS, without severely
compromising catalytic efficiency (Landis and Loeb, 1998
). By adapting
colon tumor cell lines to increasing concentrations of FdUrd, we
identified a P303L variant that conferred >20-fold resistance to both
FdUrd and AG337, 4-fold resistance to raltitrexed, and 3-fold to
BW1843U89 (Kitchens et al., 1999
).
Because a detailed kinetic scheme has been determined for ecTS and
because ecTS is, compared with human TS, intrinsically resistant to
several TS inhibitors (Jackson et al., 1993
; Spencer et al., 1997
), the
corresponding Pro to Leu substitution, along with phenylalanine,
serine, glycine, and aspartic acid, were introduced at residue 254 of
ecTS. Similar to human P303L, the P254L enzyme conferred resistance to
FdUrd and raltitrexed. However, the degree of resistance was
substantially greater (i.e., >100-fold) for the ecTS variant.
The observations that P303L in human TS is less stable than wild-type human TS, that the P254L enzyme of E. coli is sequestered into inclusion bodies, and that the purified Pro-254 mutant enzymes have decreased stability in vitro indicate that tertiary structural changes occur as a result of these mutations. With respect to kinetic and thermodynamic constants, the most drastic affects of mutations at residue 254 are impaired protein isomerization and diminished CH2H4PteGlu affinity. For instance, the affinity of the initial binding of CH2H4PteGlu forming the ternary complex is 2-fold lower for P254F, the forward isomerization rate is 7-fold slower, and the affinity after isomerization is approximately 5-fold lower compared with the wild-type enzyme. Interestingly, the P254S variant has similar steady-state values compared with the wild-type enzyme, but the isomerization reaction that is so evident for wild-type ecTS and increases the affinity of CH2H4PteGlu over 7-fold, is not observed with P254S. However, the affinity for CH2H4PteGlu, as measured by koff/kon, is not severely compromised for the P254S mutant (i.e., the Kd value for CH2H4PteGlu after protein isomerization is approximately 9 µM for wild-type ecTS and 24 µM for P254S). With respect to CH2H4PteGlu binding, P254D shows the most drastic differences compared with the wild-type enzyme in that values of Km(CH2H4PteGlu) and Kd(CH2H4PteGlu) are substantially greater than wild-type values, whereas the values of Km(dUMP), Kd(dUMP) and kcat are similar to wild-type values.
Proline 254 is located 11 amino acids from the C terminus of ecTS.
Crystal structures show that this residue is located at a bend that
directs the C-terminal residues toward the active site. On ternary
complex formation, the terminal 4-5 residues of the enzyme undergo
dramatic positional changes (Montfort et al., 1990
; Matthews et al.,
1990
). Several studies have shown that the C terminus is critical to
enzyme function (Perry et al., 1993
; Carreras and Santi, 1995
;
Spencer et al., 1997
). It can be speculated that mutations at residue
254 affect ligand binding and conformational isomerization by
perturbing the movement of the C-terminal residues. However, the
structure of P254S suggests a different mechanism. Our modeling
indicates that larger side chains at 254 must be accommodated by a
movement of the side chain of Arg-48. Although located on the surface
and apparently not directly involved in catalysis, ligand binding, or
dimer formation, Arg-48 is a highly conserved residue. This
strongly suggests that its charge is essential for the proper
functioning of TS. Larger side chains at 254 will push the guanidinium
moiety of Arg-48 into the solvent region, and the effect of its charge
will be attenuated by the high dielectric constant of water. This
hypothesis will be tested further by studying mutants of Arg-48.
In addition, the replacement of Pro-254 with serine (and presumably
other amino acids) relaxes constraints on the conformation of the main
chain and causes a rotation of the carbonyl plane of Asp-253 by about
40° (Fig. 5). This is accompanied by a shift of the side chain of
Asp-253, which forms an ion pair with Arg-225. This change is local and
does not propagate toward the C terminus. A least-squares superposition
of the high resolution structures of wild-type TS and P254S does not
show significant conformational changes in the 255-264 region. It
should be noted, however, that the structure of ternary inhibitory
complex TS/dUMP/CB3717 (Montfort et al., 1990
; Protein Data Bank entry,
2tsc) in the closed conformation also shows a shift in the position of
the side chain of Asp-253. There is no obvious link between the
conformational change at the C terminus, which involves residues
261-264, and the shift at 253 as the residues 254-260 are not
affected by the formation of the closed conformation. These
observations clearly indicate some role of Pro-254 in the transition
between the open and close conformations.
Variants of ecTS at residue 254 can potentially be used as modulators of TS-directed chemotherapy and may prove useful in providing proof-of-principle results in animal studies to show the applicability of TS as a chemoprotecting agent. Mutations at residue 254 cause impaired binding of TS-targeted antifolates, while maintaining catalytic efficiencies similar to the wild-type enzyme. The variant P254D conferred substantial resistance against raltitrexed and, of the variants studied, exhibited the most favorable properties for use in future gene transfer experiments. However, because the bacterial enzyme is being used, its applications may be limited due to the potential of immune responses.
| |
Footnotes |
|---|
Received February 1, 1999; Accepted September 9, 1999
1 This work was supported by Grants CA 78651 and CA 76560 from the National Cancer Institutes.
Send reprint requests to: H. Trent Spencer, Department of Biological Sciences, University of South Carolina, Columbia, SC 29208. E-mail: spencer{at}psc.sc.edu
| |
Abbreviations |
|---|
DHFR, dihydrofolate reductase; TS, thymidylate synthase; ecTS, Escherichia coli TS; CH2H4PteGlu, methylenetetrahydrofolate; PCR, polymerase chain reaction; FdUrd, 5-fluoro-2'-deoxyuridine; MES, 2-(N-morpholino)ethanesulfonic acid.
| |
References |
|---|
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||